Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

 Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends

Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, CA, October 5, 2020 – Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug Application (“NDA”) for mavacamten for the treatment of symptomatic obstructive HCM – based on data from the EXPLORER-HCM study – is expected to be submitted to the U.S. Food and Drug Administration (“FDA”) in the first quarter of 2021. Bristol Myers Squibb expects to explore the full potential of mavacamten in additional indications, including non-obstructive HCM, as well as develop MyoKardia’s promising pipeline of novel compounds, including two clinical-stage therapeutics: danicamtiv (formerly MYK-491) and MYK-224.

“The acquisition of MyoKardia further strengthens our portfolio, pipeline and scientific capabilities, and is expected to add a meaningful medium- and long-term growth driver,” said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer of Bristol Myers Squibb. “We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease. Our companies share a commitment to innovation and bold science, and our respective strengths will help us realize the value inherent in this portfolio. We have long admired MyoKardia and what they have done to revolutionize cardiovascular treatments through a precision medicine approach. We look forward to welcoming their talented team to our company.”

“MyoKardia was formed eight years ago with the aim of changing the world for people with serious cardiovascular diseases through bold and innovative science. Since then, MyoKardia’s dedicated employees have established an unparalleled pipeline of targeted therapeutics designed to change the course of disease and return the heart to normal function,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia. “Bristol Myers Squibb shares our vision for transforming the treatment of cardiovascular disease. They value our team and the potential of our platform and, most importantly, share our unwavering commitment to placing patients at the center of everything we do. Together, our complementary strengths and expanded resources and reach will further accelerate the pace at which we can discover, develop and commercialize our novel medicines for the benefit of people suffering from cardiovascular disease around the world.”

Compelling Benefits

Bristol Myers Squibb expects the transaction, when complete, to:

With the high unmet medical need in obstructive HCM, mavacamten can be a significant medium- and long-term growth driver. Mavacamten demonstrated clinically meaningful results in the pivotal Phase 3 EXPLORER-HCM trial, meeting the primary and all secondary endpoints, and showed meaningful improvements in symptoms, functional status and quality of life by reducing the obstruction of blood flow from the heart. This potential first-in-class medicine, for which an NDA is expected to be submitted to the FDA in the first quarter of 2021, may help to change the course of the disease.

Bristol Myers Squibb has established Eliquis® (apixaban) as the #1 oral anticoagulant globally with a best-in-class profile, driven by leading commercial execution. Mavacamten will be a fully owned asset that fits well into Bristol Myers Squibb’s existing portfolio, given the company’s broad expertise in cardiovascular disease. Through this acquisition, Bristol Myers Squibb gains MyoKardia’s critical talent and capabilities on the U.S. West Coast, which will support fully realizing the opportunity in obstructive HCM and exploring the full potential of mavacamten in additional indications. Bristol Myers Squibb will also be well positioned to advance the global development of MyoKardia’s portfolio of clinical- and early-stage pipeline candidates, while continuing to advance its existing Factor XIa inhibitor program.

The transaction is expected to add a significant growth driver during the medium- to long-term. It is expected to be minimally dilutive to Bristol Myers Squibb’s non-GAAP earnings per share (EPS) in 2021 and 2022 and accretive beginning in 2023. Bristol Myers Squibb reaffirms its existing 2021 non-GAAP EPS guidance range. There is no reliable estimable comparable GAAP measure as described below.

Transaction Terms and Financing

Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of MyoKardia’s common stock for $225.00 per share in cash. MyoKardia’s Board of Directors unanimously recommends that MyoKardia shareholders tender their shares in the tender offer.

The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of MyoKardia’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of MyoKardia that are not tendered into the tender offer through a second-step merger at the same price of $225.00 per share.

Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. HCM is estimated to affect one in every 500 people.

The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In approximately two-thirds of HCM patients, the path followed by blood exiting the heart, known as the left ventricular outflow tract (LVOT), becomes obstructed by the enlarged and diseased muscle, restricting the flow of blood from the heart to the rest of the body (obstructive HCM). In other patients, the thickened heart muscle does not block the LVOT, and their disease is driven by diastolic impairment due to the enlarged and stiffened heart muscle (non-obstructive HCM). In either obstructive or non-obstructive HCM patients, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

There are currently approximately 160,000 to 200,000 people diagnosed with symptomatic obstructive HCM across the U.S. and EU, with no existing effective treatment options beyond limited symptomatic relief. Patients are typically diagnosed in their 40s or 50s and the treatment is expected to be chronic. It is estimated that only approximately 25 percent of individuals with obstructive HCM and only approximately 10 percent of individuals with non-obstructive HCM have received a diagnosis.

Conference Call

At 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time today, Bristol Myers Squibb will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of the call can be accessed at Bristol Myers Squibb’s Investors page at bms.com/investors. Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that may be required. Alternatively, please call (877) 658-9096 (U.S.) or (602) 563-8733 (international) and dial the conference ID 9697843 to access the call.

Telephone replay will be available approximately three hours after the call until 11:30 a.m. ET on October 19, 2020. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international) and dial the conference ID 9697843. The webcast will be archived on bms.com/investors.

Advisors

Gordon Dyal & Co., LLC is serving as exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Centerview Partners LLC and Guggenheim Securities are acting as joint financial advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Additional Information and Where to Find It

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov. INVESTORS AND MYOKARDIA’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Cautionary Statement Regarding Forward Looking Statements

This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are generally identified by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks are (i) that there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized, (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement and (iii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in MyoKardia’s most recent Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports filed on Form 10-Q with the SEC, as well as other documents that may be filed by MyoKardia from time to time with the SEC. Neither Bristol Myers Squibb nor MyoKardia undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

Use of Non-GAAP Financial Information and Financial Guidance

This release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Non-GAAP information is intended to portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information are indications of the company’s baseline performance before items that are considered by us to not be reflective of the company’s ongoing results. In addition, this information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

There is no reliable or reasonably estimable comparable GAAP measure for this non-GAAP financial guidance because we are not able to reliably predict the impact of specified items beyond 2020. As a result, reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results.

In addition, the non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

Contacts

Bristol Myers Squibb

Media:

media@bms.com

609-252-3345

Investors:

Tim Power, 609-252-7509, timothy.power@bms.com

Nina Goworek, 908-673-9711, nina.goworek@bms.com

MyoKardia

Michelle Corral

Executive Director, Corporate Communications and Investor Relations

MyoKardia, Inc.

650-351-4690

ir@myokardia.com

Hannah Deresiewicz (investors)

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Julie Normart (media)

W2O

628-213-3754

jnormart@w2ogroup.com

 Bristol Myers Squibb to Acquire MyoKardia  October 5, 2020 

 Additional Information and Where to Find It The tender offer described in this report has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file with the U.S. Securities and Exchange Commission (“SEC”) a tender offer statement on Schedule TO. Investors and MyoKardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by MyoKardia with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www.myokardia.com or by contacting MyoKardia at ir@myokardia.com, telephone number 650-351-4690. In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov. Forward Looking Statements This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Bristol Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Use of Non-GAAP Financial Information and Financial GuidanceThis earnings release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Non-GAAP information is intended to portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information are indications of the company’s baseline performance before items that are considered by us to not be reflective of the company’s ongoing results. In addition, this information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. There is no reliable or reasonably estimable comparable GAAP measure for this non-GAAP financial guidance because we are not able to reliably predict the impact of specified items beyond 2020. As a result, reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. In addition, the non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.  2 

         Agreement toacquire MyoKardiafor:$13.1B$225/share in cash   Bristol Myers Squibbto gain access to:MavacamtenFirst-in-class specialty CV medicinewith significant commercial potential CV pipeline and discovery capabilities  Significantmedium- and long-term growth opportunity; accretive to revenue and Non-GAAP EPS starting in 2023  All-cash transactionvia tender offer expected to closein Q4 2020 subject to customary reviews  Transaction overview  3  Significant opportunity for value creation for BMS 

         We are well positioned to advance our strategy  Pipeline New product approvals: Reblozyl, Zeposia, Onureg (CC-486)Multiple BLAs/NDAs in progress: liso-cel, ide-cel Two 1L lung approvals: Checkmate 227 and Checkmate 9LADelivered positive results on key clinical trials: Zeposia in UC, Checkmate 9ER, Checkmate 743, Checkmate 649, Checkmate 577, Checkmate 274  CommercialStrong commercial execution, delivering continued topline growth  IntegrationActivities proceeding well, synergies on track  FinancialFinancial strength and P&L discipline  4 

 Consistent approach to sustaining innovation and renewing our portfolio  5  Research & DevelopmentWorld class talent & approachProprietary datasets & platformsRobust pipeline  Business DevelopmentA top priority for capital allocationConsistent evaluation criteriaEnabled by financial strength & flexibility  17 marketed medicines, many have opportunities for additional indications 7 assets in registrational development>50 assets in Ph I or Ph II trials 

 MyoKardia: Innovative biotech focused on specialty CV  6  mavacamten: A first-in-class myosin inhibitor De-risked lead-indicationPositive Ph3 (EXPLORER) trial for obstructive Hypertrophic Cardiomyopathy (HCM) with strong efficacy and good tolerability profileReceived Breakthrough Therapy Designation inJuly 2020; on track to be filed with FDA in Q1 2021Additional indications e.g. non-obstructive HCM  ~300 employees with significant expertise in cardiovascular  Located inSan Francisco Bay Area  Complementary patient-centric cultures    Obstructive HCM (completed)  P1  P3  Non-obstructive HCM  Precision diastolic disease (mavacamten HFpEF)  HCM  Systolic dysfunction and atrial fibrillation  Genetic dilated cardiomyopathy (DCM)  P2    LUS-1  ACT-1  Precision diastolic diseases (preclinical)  Precision systolic diseases (preclinical)  MYK-224  danicamtiv  mavacamten  PIPELINE 

     FXIa inhibitor         Transaction accelerates expansion of leading CV franchise  7  *Assuming District Court ruling upheld upon appeal, no other generics overturn current patents; VTEp: Venous Thromboembolism prevention; TKR: Total Knee Replacement; SSP: Secondary Stroke Prevention  Best-in-class medicine with strengthened IP positionPotential additional exclusivity post 2026  Fully-owned growth driver with potential 2021 launchBMS commercial capabilities are well positioned to realize the full value of the opportunity  Potential next-generation antithromboticPh2 data in VTEp TKR study and SSP study expected next year and 2022  Eliquis        mavacamten   

       Hypertrophic cardiomyopathy (HCM) disease profile  8    Normal Heart  Hypertrophic Heart  Decreased left ventricular volume  Thickened heart muscle and septum  LVOT1 obstruction  Diagnosed by echo-cardiogram  Subset of patients have severe symptoms  Typical age of diagnosis in the ~40s-50s  HCM Pathophysiology  Enhanced cardiac actin-myosin interactionsHypercontractility and thickening of the heart muscle  HCM Prevalence  ~1 in 500 people (total population)Most common genetic heart disease   Classification  Obstructive HCM: mechanical obstruction of blood flow out of left ventricle (~2/3 of patients)Non-obstructive HCM: ~1/3 patients  ~25% of obstructiveHCM and ~10% of non-obstructive HCM patients are symptomatic and diagnosed  1. LVOT = Left ventricular outflow tractSource: Olivotto. Lancet. 2020; Maron. NEJM. 2018; Marian. Circ Res. 2017; Maron. J Am Coll Cardiol. 2016; Veselka. Lancet. 2016; Maron. J Am Coll Cardiol. 2015; Ahmad. Annu Rev Genomic Hum Genet. 2005; Maron. JAMA. 1999; Maron. Circulation. 1995.  

   Significant unmet need for patients with symptomatic obstructive HCM  9  Symptoms have a meaningful negative impact on quality of lifeComplications can be severe, including:heart failuremitral valve prolapse and regurgitationatrial fibrillationsudden cardiac death      Source: Maron. NEJM. 2018; Geske. JJAC Heart Fail. 2018; Marian. Circ Res. 2017; Maron. Am J Cardiol. 2016; Veselka. Lancet. 2016. Maron. Circulation. 1995.   Patients with Symptomatic Obstructive HCM  80–100K U.S.   80–100KEU  Currently no approved medicines that address underlying disease      Current management is limited to symptomatic relief, compensation via lifestyle changes, or invasive proceduresMedical therapy: non-specific and only offers symptomatic improvementSurgical therapy: typically for patients with severe obstructive HCM and include septal or apical myectomy, septal ablation 

   Mavacamten: a potential first-in-class medicine that could treat underlying disease   10  Source: Olivotto. Lancet. 2020.  Normal Sarcomere  HCMSarcomere  HCM Sarcomere with mavacamten  Actin thin filament  Actin-myosin cross-bridge  Myosin thick filament  First-in-class Myosin ATPase inhibitor    Mavacamten’s mechanism of action is specific to cardiac muscleInhibition of myosin cross-bridge formation has a direct impact on underlying disease Reduction of cross-bridges inhibits excessive contractility and hypertrophic stimulus    mavacamten 

   Mavacamten: EXPLORER-HCM Study Design  11    1Ho CY et al. Circ Heart Fail. 2020; 13(6):e006853  Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients With Obstructive HCM1  NYHA Class II/IIIPeak LVOT gradient ≥ 50mmHgLVEF ≥ 55%Background medications allowed    Primary endpoint: functional composite of either (1) ≥ 1.5-mL/kg/min improvement in peak VO2 plus improvement of > 1 NYHA functional class, or (2) ≥ 3.0-mL/kg/min improvement of peak VO2 with no worsening in NYHA functional class at week 30Secondary endpoints: post-exercise LVOT gradient, peak VO2, NYHA class, and quality of life and shortness of breath scores  Inclusion criteria  N=251  Screening  Randomization  Washout                              mavacamten  placebo          5mg QD  10mg QD5mg QD2.5mg QD  15mg QD10mg QD5mg QD2.5mg QD  -W4  D1  W1  W2  W6  W12  W13  W14  W28  W30  W38  W7  W8      DOSE ADJUSTMENT  DOSE ASSESSMENT     

 Mavacamten: Compelling Ph3 efficacy profile in symptomatic obstructive HCM  12  [Key Data]  [Key Data]        Mavacamten group (n=123)  Placebo group (n=128)  Difference* (95% CI),p value  Primary endpoint†          Either ≥1.5 mL/kg per min increase in pVO2 with ≥1 NYHA class improvement or ≥3.0 mL/kg per min increase in pVO2 with no worsening of NYHA class     45 (37%)  22 (17%)  19.4 (8.7 to 30.1; p=0.0005)     Both ≥3.0 mL/kg per min increase in pVO2 and ≥1 NYHA class improvement  25 (20%)   10 (8%)   12.5 (4.0 to 21.0)  Secondary endpoints‡          Post-exercise LVOT gradient change from baseline to week 30, mm Hg    –47 (40), n=117  –10 (30), n=122  –35.6 (–43.2 to –28.1; p<0.0001)  pVO2 change from baseline to week 30, mL/kg per min    1.4 (3.1), n=120  –0.1 (3.0), n=125  1.4 (0.6 to 2.1; p=0.0006)  ≥1 NYHA class improvement from baseline to week 30§    80 (65%)  40 (31%)  34% (22 to 45; p<0.0001)  Change from baseline to week 30 in KCCQ-CSS§ (QoL)    13.6 (14.4), n=92  4.2 (13.7), n=88  9.1 (5.5 to 12.7; p<0.0001)  Change from baseline to week 30 in HCMSQ-SoB§ (QoL)    -2.8 (2.7), n=85  –0.9 (2.4), n=86  –1.8 (–2.4 to –1.2; p<0.0001)  Exploratory endpoint          Complete response, n/N (%) Defined as NYHA Class I and all LVOT gradients <30 mm Hg    32/117 (27%)  1/126 (1%)  26.6% (18.3% to 34.8%)  Data are n (%) or mean (SD). HCMSQ-SoB = Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore. KCCQ-CSS = Kansas City Cardiomyopathy Questionnaire-Clinical Symptom Score. LVOT = Left ventricular outflow tract. pVO2 = Peak oxygen consumption. NYHA=New York Heart Association. *Model estimated least-square mean differences were reported for continuous variables. †Patients with a non-evaluable primary endpoint and NYHA secondary endpoint were considered as non-responders. The response rates were calculated with the N value as the denominator. ‡N was the number analysable for secondary endpoints based on availability of both baseline and week 30 values. §Due to the smaller numbers evaluable for patient-reported outcome endpoints, additional post-hoc analyses compared the reasons for missing data. Adapted from Olivotto. Lancet. 2020. 

 Mavacamten: 97% completion rate through 30 weeks of treatment  Adverse eventsPreferred term  Mavacamten(n = 123)  Placebo(n = 128)  Patients with ≥1 TEAEs, n (%)  108 (87.8)  101 (78.9)  Total number of SAEs  11  20  Patients with ≥1 SAE, n (%)  10 (8.1)  11 (8.6)  Atrial fibrillation  2 (1.6)  4 (3.1)  TIA  0  1 (0.8)  Syncope  2 (1.6)  1 (0.8)  Stress cardiomyopathy  2 (1.6)  0  Cardiac failure congestive  0  1 (0.8)  Sudden death  0  1 (0.8)  13  3 patients discontinueddue to AEs:2 on mavacamten,1 on placeboNo patients withdrew due to reduced LVEF or symptoms of heart failure   SAE, serious adverse event; TEAE, treatment-emergent adverse event.  Adapted from Olivotto. Lancet. 2020. 

 Future mavacamten indications and pipeline opportunities  14   Obstructive HCM (completed)  P1  P3  Non-obstructive HCM  Precision diastolic disease (mavacamten HFpEF)  HCM  Systolic dysfunction and atrial fibrillation  Genetic dilated cardiomyopathy (DCM)  P2    LUS-1  ACT-1  Precision diastolic diseases (preclinical)  Precision systolic diseases (preclinical)  MYK-224  danicamtiv  mavacamten  PIPELINE 

 Mavacamten: significant commercial opportunity in symptomatic obstructive HCM  15        Robust Clinical Data  First-to-market  Strong SpecialtyValue  Source: Maron. NEJM. 2018; Marian. Circ Res. 2017; Maron. Am J Cardiol. 2016; Maron. Circulation. 1995.   Addresses underlying disease and improves quality of lifeFirst-to-marketOpportunity to achieve value consistent with chronic specialty CV products    160–200K symptomatic patients across the U.S. and EU are in immediate need of treatment    mavacamten 

 Expanded to the broader cardiology community, then PCPsNow focused on increasing share and increasing diagnosis rates    BMS uniquely positioned to realize the full value of mavacamten  16  Established Eliquis as standard of care, despite late entry to market with entrenched SOCInitially established best-in-class profile with key cardiology accounts  mavacamten      Medical / Commercial /Value & Access  Launch-ready infrastructure enables a strong first-to-market position in high-need areaIntroduce new medicine to specialist centers(20% of patients treated)Expand to broader cardiology settingBroaden physician education on the disease withlong-term opportunity to increase diagnosis rates       

 Symptomatic obstructive HCM opportunity  High unmet needMavacamten: first medicine with potential to treat underlying diseaseSignificant commercial opportunityBMS uniquely positioned to commercialize   17 

 Significant financial benefits  18  Clear opportunity for value creation and P&L growthTransaction IRR in excess of MyoKardia’s WACCMavacamten launch indication is significant and supports the transaction Additional indications and pipeline provide incremental valueSignificant medium- and long-term growth opportunity Accretive to revenue and Non-GAAP EPS starting in 2023  Transaction details$13.1B total considerationAll-cash deal via tender offer, no financing contingencyExpect to use cash and debt while retaining strong investment grade credit ratings   

 Consistent approach to capital allocation  19  Continued commitment to the dividend*  Committed to reducing debt:<1.5x Debt / EBITDA by end of 2024  Future innovation through business development  *Subject to board approval 

 MyoKardia: Strong strategic fit and financially attractive  20    Compelling Opportunity  First-in-class, specialty CV medicine addressing high unmet need, with significant commercial potential in the lead indication and upside potential from additional indications and pipeline; Obstructive HCM to be filed in Q1 2021  Strengthens CV franchise  Broadens and accelerates expansion of CV portfolio & pipelineFull ownership  Strong Value Rationale  Generates IRR in excess of MyoKardia’s WACCMavacamten in obstructive HCM (launch indication) is a significant opportunitythat supports the transaction, with further opportunities from additional indications and pipeline  Supports P&L Growth  Significant medium- and long-term growth opportunity; Accretive to revenue and Non-GAAP EPS starting in 2023 & substantial impact in the second half of the decadeMeaningful growth driver in the medium- and long-term including into the2H of the decade  Consistent Capital Allocation  Remains focused on disciplined BD, improving leverage and reaching 1.5x Debt/EBITDA in 2024 while committed to the dividend 

 Q&A  Giovanni Caforio, M.D.Board Chair,Chief Executive OfficerDavid ElkinsExecutive VP,Chief Financial Officer  21  Chris Boerner, Ph.D.Executive VP,Chief Commercialization OfficerSamit Hirawat, M.D.Executive VP,Chief Medical Officer,Global Drug Development 

 Corrected Transcript  Total Pages: 21      05-Oct-2020  1-877-FACTSET www.callstreet.com  Copyright © 2001-2020 FactSet CallStreet, LLC  Bristol Myers Squibb Co. (BMY)Acquisition of MyoKardia by Bristol Myers Squibb Co Call 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      CORPORATE PARTICIPANTS  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com  Tim PowerVice President-Investor Relations, Bristol Myers Squibb Co.Giovanni CaforioChairman & Chief Executive Officer, Bristol Myers Squibb Co.Samit HirawatExecutive Vice President & Chief Medical Officer-Global Drug Development, Bristol Myers Squibb Co.  Christopher S. BoernerExecutive Vice President & Chief Commercialization Officer, Bristol Myers Squibb Co.David V. ElkinsChief Financial Officer & Executive Vice President, Bristol Myers Squibb Co.  ......................................................................................................................................................................................................................................................  OTHER PARTICIPANTSSeamus FernandezAnalyst, Guggenheim Securities LLCTerence FlynnAnalyst, Goldman Sachs & Co. LLCTim AndersonAnalyst, Wolfe Research LLCChris SchottAnalyst, JPMorgan Securities LLCSteve ScalaAnalyst, Cowen & Co. LLC  Geoff MeachamAnalyst, Bank of America Merrill LynchLuisa HectorAnalyst, Joh. Berenberg, Gossler & Co. KG (United Kingdom)Matt PhippsAnalyst, William Blair & Co. LLCNavin JacobAnalyst, UBS Securities LLCDavid R. RisingerAnalyst, Morgan Stanley & Co. LLC 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      MANAGEMENT DISCUSSION SECTION  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com  Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Bristol Myers Squibb Acquisition of MyoKardia. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]I would now like to hand the conference over to your speaker today, Tim Power, Vice President of Investor Relations. Please go ahead, sir.......................................................................................................................................................................................................................................................Tim PowerVice President-Investor Relations, Bristol Myers Squibb Co.Right. Thanks, Sonia, and good morning, everyone. Thanks for joining us today for our call to discuss our acquisition of MyoKardia. Joining me today are Giovanni Caforio, our Board Chair and Chief Executive Officer; along with David Elkins, our Chief Financial Officer; Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development; and Chris Boerner, our Chief Commercialization Officer.As a reminder, a slide presentation and press release regarding today's news are available on the Investor Relations section of Bristol Myers Squibb's website. I will refer you to slide 2 of today's presentation for our legal disclosures.And with that, I'd like to hand the call over to Giovanni, starting on slide 3.......................................................................................................................................................................................................................................................Giovanni CaforioChairman & Chief Executive Officer, Bristol Myers Squibb Co.Thank you, Tim. Good morning, everyone. Today is an exciting day for Bristol Myers Squibb. Through our $13.1 billion all-cash acquisition of MyoKardia, we are further strengthening our company's future outlook as we bring into the company a potentially transformative new medicine with potential for launch in 2021 and accelerate the expansion of our cardiovascular franchise for today and for tomorrow. We expect to commence a tender offer promptly and close the transaction by the end of the year.MyoKardia is a clinical-stage biopharmaceutical company that focuses on cardiovascular disease. Since its founding in 2012, MyoKardia's talented team has used its scientific expertise to develop a potentially first-in-class lead asset called mavacamten and a promising portfolio of pipeline candidates. Bristol Myers Squibb has a long history of discovering, developing and delivering medicines that treat patients with serious cardiovascular disease. And the addition of MyoKardia aligns with our strategy and complements our business very well.In the near term, the acquisition of MyoKardia brings mavacamten, which potentially offers a very important option for patients with cardiovascular disease and an exciting opportunity for the company. Mavacamten has demonstrated clinically-meaningful Phase 3 results for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy or obstructive HCM. Obstructive HCM is a cardiovascular disease with high morbidity and patient impact, which Samit will discuss in more detail later. We believe mavacamten has multi- billion dollar revenue potential. And we are excited about the opportunity to improve the lives of more patients with cardiovascular disease around the world. 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      Turning to slide 4. Clearly, today's announcement is an important step in continuing to execute against our strategy, focused on growth and innovation. And I believe our strategy is delivering. Let me provide a high-level overview of where we are as a company and how this transaction fits. We will soon complete our first year following the acquisition of Celgene. So, let me start by saying that I am extremely proud of our accomplishments over the past year, particularly in the face of a global pandemic. I continue to be even more encouraged about our opportunities than in the past. We are delivering strong commercial performance, achieved three new product approvals, continued to add new indications and multiple positive clinical trial results with OPDIVO, advanced our pipeline and further strengthened our financial position.We have done all of this while successfully advancing our integration. Our strong execution and financial flexibility position us well, and it is thanks to the strong foundation we have built that we can continue to advance our strategy. The acquisition of MyoKardia represents a unique opportunity to further expand our portfolio by adding an important growth driver to the company.Let's turn to slide 5, which is based on a slide you would have seen earlier this year. I show this slide for two reasons, firstly, because I continue to be very encouraged by the breadth of opportunities we have as a company across our pipeline and portfolio; secondly, because I want to remind you of our long-standing strategy of maximizing the value of our own pipeline, while complementing our internal portfolio with external innovation. In fact, we have been active in accessing important innovation this year with a number of promising pipeline additions. This strategic approach has served us well by ensuring that we are sourcing the best science and developing the most exciting medicines.Turning to slide 6, where you can see a bit more background on MyoKardia. MyoKardia has around 300 extremely talented and dedicated employees based in the Bay Area, who share our patient-focused culture and passion for addressing unmet medical needs in serious disease. We have long admired their work to revolutionize cardiovascular treatments through a precision approach. And their development efforts today are impressive.Their lead compound, mavacamten, based on the efficacy and safety data we have already seen, has significant potential in obstructive HCM and further opportunities in additional indications. In addition, MyoKardia has a promising pipeline of novel compounds, including two clinical stage therapeutics: danicamtiv, MYK-491; andMyoKardia, MYK-224. These compounds will bolster our leading cardiovascular franchise. Importantly, this is a disease area that we know very well, and it is one where we have a strong track record of developing and commercializing very successful medicines that benefit patients.Turning to slide 7. I am very proud of the cardiovascular franchise we have built. As you can see here, with MyoKardia, we are extending our leading cardiovascular position. We have a leg of developing transformational cardiovascular medicines, including Plavix and Eliquis. We built Eliquis into the number one oral anticoagulant globally with a best-in-class profile, despite being third to market. We achieved this success with a huge development and strong commercial execution. And I feel confident that the recent IP developments related to Eliquis give us some additional runway.Importantly, we also continue to advance development of our Factor XIa inhibitor. We believe this could be another transformational medicine for the treatment of thrombotic diseases. When you layer mavacamten on top of this strong foundation, the opportunities are significant. Mavacamten recently showed compelling Phase 3 data, meeting the primary and all secondary endpoints as well as demonstrating meaningful improvements in symptoms, functional status and quality of life.  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      I would like to also highlight that, unlike Eliquis, mavacamten will be a fully-owned asset. Taken together, this asset fits very well into our existing portfolio. And we are the right company to maximize its potential for patients, given our broad expertise and proven commercial capabilities in this area.I will now turn it over to Samit to discuss why HCM is such an important disease to treat and how mavacamten addresses a significant unmet need. Chris will then talk about why we are so excited about the commercial potential. And David will wrap up with a discussion on the financials.Samit?......................................................................................................................................................................................................................................................Samit HirawatExecutive Vice President & Chief Medical Officer-Global Drug Development, Bristol Myers Squibb Co.Thank you, Giovanni. Let me turn to slide 8 and take a few minutes to tell you about hypertrophic cardiomyopathy or HCM for short. HCM is actually quite a prevalent condition, estimated to affect at least 1 in 500 people globally. Though, as I'll explain in a moments, only a minority of patients have symptomatic disease and get diagnosed.Frequently, this condition is a result of a genetic mutation. And fundamentally, it is associated with enhanced interactions between actin and myosin fibers in the cardiac muscle, which results in thickening or hypertrophy ofthe heart muscle, thus the name hypertrophic cardiomyopathy.You can see that on the illustrations on the left of the slide which shows a healthy heart on the top along with hypertrophy of the left ventricle in the picture below. Within hypertrophic cardiomyopathy, about 2/3 of people have obstructive disease, meaning there is a mechanical obstruction of blood flow from the left ventricle. About 25% of these obstructive hypertrophic cardiomyopathy patients are symptomatic. The other 1/3 of the HCM patients have non-obstructive disease. Importantly, with obstructive or non-obstructive hypertrophic cardiomyopathy patients, it's the symptomatic patients that are in need of treatment. Their symptoms can be severe, and their disease is progressive. Patients typically are diagnosed in their 40s or 50s. And with a progressive disease like this, the treatment is expected to be chronic.Now, turning to slide 9 and focusing specifically on symptomatic obstructive hypertrophic cardiomyopathy. Here, you get a sense of the uphill battle that these patients are facing. Currently, there are 80,000 to 100,000 patients in each the United States and Europe who are symptomatic and diagnosed obstructive hypertrophic cardiomyopathy patients. These patients deal with fainting, fatigue, shortness of breath, limitation of physical activity and they are at increased risk of serious cardiac events, including arrhythmias and even sudden cardiac death. Importantly, the only options these patients today have are highly-invasive surgical procedures, such as myectomy or drugs such as beta blockers and calcium channel blockers that provide limited symptom relief, but do nothing to address the underlying cause of the disease. Clearly, for these patients, there is a real need for a new medicine that can treat their symptoms and address the underlying condition that causes those symptoms.Now, allow me to spend some time on slide 10 to tell you about mavacamten and why the scientific research that MyoKardia has driven provides a very important potential treatment for HCM. Put simply, mavacamten is intended to inhibit excessive myosin-actin cross-bridge formation in a cardiac muscle. This in turn is believed to reduce the excessive contractility caused by the excessive muscle mass in the heart with minimal to no impact on skeletal muscle. Because mavacamten reduces contractility of the heart, the dose of mavacamten will need to be managed carefully to not relax the heart too much. Beyond the interesting mechanism of action, however, let me tell you next about the existing or exciting clinical data that's been generated in patients with obstructive HCM.  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      And thus, turning to slide 11, you can see the EXPLORER-HCM study design. This was a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial in patients with symptomatic obstructive HCM. It was designed to evaluate the first potential targeted medical therapy for these patients.Patients had to have clear evidence of obstruction of blood flow from the left ventricle, as measured by left ventricle outflow tract gradient, or LVOT gradient, more than or equal to 50 millimeters of mercury; and they had to have clear symptoms as defined by New York Heart Association, or NYHA Class II or Class III for heart failure. Left ventricular ejection fraction had to be greater than or equal to 55%. In other words, this trial recruited patients whose disease is seriously affecting their lives.As you know, under the NYHA classification, patients with Class II symptoms though classified as mild live with shortness of breath and/or angina and some limitation of ordinary activity. Patients with Class III disease live with a significant limitation in activity, including being very limited in the distance they can walk. Less than ordinary activity in these patients results in debilitating symptoms, including fatigue, palpitations and/or shortness of breath.Patients were randomized to receive mavacamten or placebo for 30 weeks. Patients began treatment on a 5- milligram dose once a day for mavacamten or a matching placebo, with dose titration at weeks 8 and 14, and were allowed to continue background concomitant medications for HCM symptom management.The primary endpoint of the study was composite of improvements in cardiac function and symptoms. Cardiac function was measured using oxygen consumption, or peak VO2, which is an objective measure of patients' performance on cardiopulmonary exercise testing. Improvement in symptoms was assessed using changes in the NYHA class of heart failure.To be considered a responder, the patient was required to either perform better on both measures or show a higher improvement in oxygen consumption while maintaining their symptom class. There were also several secondary endpoints, including post-exercise LVOT gradient, oxygen consumption as measured by peak VO2, proportion of patients with greater than or equal to one NYHA class improvement, quality of life, safety and others.Looking at the EXPLORER-HCM study results on slide 12, let me share with you a few observations. First, with respect to the primary endpoint at the end of 30 weeks of treatment, 37% of patients on mavacamten achieved the primary endpoint, nearly a doubling of response rate compared to that seen in the placebo arm of 17%. This difference was highly statistically significant.Additionally, 20% of patients on mavacamten met both at least a 3 milliliters per kilogram per minute increase in peak VO2 and at least one NYHA class improvement versus 8% of those on placebo, also highly statistically significant.Now, let me draw your attention to some of the secondary endpoints. Mavacamten was associated with significant improvement in all secondary endpoints compared to placebo, including demonstrating a greater reduction inpost-exercise LVOT gradient of 36 millimeters of mercury and a greater increase in peak VO2 by 1.4 milliliters per kilogram per minutes versus placebo. Now, this is important as this is telling us that there is a reduction in obstruction and an increase in the ability to consume oxygen.Turning to symptoms again. A remarkable 65% of mavacamten-treated patients saw symptom improvement, as demonstrated by an improvement of one or more NYHA class, representing twice as many achieving this  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com 

 Bristol Myers Squibb Co. (BMY) Acquisition of MyoKardia by Bristol Myers Squibb Co Call  Corrected Transcript05-Oct-2020      Tim and his team will remain available to all of you during the course of the day and the next few days this week to answer any questions you may have and we look forward to continuing the dialogue. Thanks for dialing into the call at short notice today. Thanks everyone and have a good day.......................................................................................................................................................................................................................................................Operator: Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.  *Copyright © 2001-2020 FactSet CallStreet, LLC  1-877-FACTSET www.callstreet.com  DisclaimerThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error-free statement or summary of the available data. As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. You must evaluate, and bear all risks associated with, the use of any information provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. This information is not intended to be used as the primary basis of investment decisions. It should not be construed as advice designed to meet the particular investment needs of any investor. This report is published solely for information purposes, and is not to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Any information expressed herein on this date is subject to change without notice. Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSet CallStreet, LLC. FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a position in any of the securities discussed herein.THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS," AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020 CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. All other trademarks mentioned are trademarks of their respective companies. All rights reserved. 

 Bristol Myers Squibb to Acquire MyoKardia                        Accelerates the expansion of our cardiovascular portfolioPlanned acquisition fits well into BMS’s existing portfolio given broad expertise in CV diseaseEstablished Eliquis as the #1 oral anticoagulant globally with best-in-class profile, driven by leading commercial executionWell positioned to advance global development of MyoKardia’s portfolio – promising pipeline includes danicamtiv (formerly MYK-491) and MYK-224Mavacamten will be a fully owned asset; demonstrated clinically meaningful results in pivotal Phase 3 EXPLORER-HCM trialWill explore mavacamten in additional indications, including non-obstructive HCM  Further strengthens our outlook with the addition of mavacamten  Mavacamten will be a meaningful medium- and long-term growth driver presenting a significant commercial opportunity upon approvalExpected to be accretive to non-GAAP EPS starting in 2023IRR in excess of MyoKardia WACC  Strong returns and accretion  Source: Maron. NEJM. 2018; Marian. Circ Res. 2017; Maron. Am J Cardiol. 2016; Maron. Circulation. 1995.  Bristol Myers Squibb has agreed to acquire MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through this transaction, BMS gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophiccardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. An NDA for mavacamten for symptomatic obstructive HCM is expected to be submitted to the FDA in Q1 2021. BMS also expects to explore the full potential of mavacamten in additional indications and develop MyoKardia’s promising pipeline of novel compounds.        160–200Kdiagnosed, symptomatic obstructive HCM patients across the U.S. and EU are in immediate need of treatment      Addresses underlying disease and improves quality of life  First-to-market  Ability to achieve value consistent with chronic specialty CV products          Robust Clinical Data  First-to-  market    Strong  Specialty  Value      mavacamten        Transaction Terms        Expected to close in Q4 2020  Subject to customary conditions  $13.1 billion all cash acquisition via tender offer 

 Additional Information and Where to Find ItThe tender offer described in this report has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file with the U.S. Securities and Exchange Commission (“SEC”) a tender offer statement on Schedule TO. Investors and MyoKardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/ recommendation statement on Schedule 14D-9 that will be filed by MyoKardia with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www.myokardia.com or by contacting MyoKardia at ir@ myokardia.com, telephone number 650-351-4690.In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.Forward Looking StatementsThis report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Bristol Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.Use of Non-GAAP Financial Information and Financial GuidanceThis release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Non-GAAP information is intended to portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information are indications of the company’s baseline performance before items that are considered by us to not be reflective of the company’s ongoing results. In addition, this information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.There is no reliable or reasonably estimable comparable GAAP measure for this non-GAAP financial guidance because we are not able to reliably predict the impact of specified items beyond 2020. As a result, reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results.In addition, the non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. 

Bristol Myers Squibb @bmsnews We are excited to announce our acquisition of  @MyoKardia , which further strengthens our portfolio, pipeline and scientific capabilities, and is expected to add a meaningful medium- and long-term growth driver. For more information & cautionary statements: https://bit.ly/2SuBetI 6:39 AM • Oct 5, 2020•Sprinklr

---

Bristol Myers Squibb @bmsnews We share a commitment to innovation and bold science with  @MyoKardia , and our respective strengths will help us realize the value inherent in this portfolio. For more information and cautionary statements: https://bit.ly/3lexgS7 10:58 AM • Oct 5, 2020•Sprinklr

 

---

Bristol Myers Squibb 811,925 followers 7h  At BMS, we are united around a single vision: transforming patients’ lives through science. Find out about our latest opportunity to help patients with serious cardiovascular disease https://bit.ly/33wXNE9.

 

---

Bristol Myers Squibb 7 hrs •  At BMS, we are united around a single vision: transforming patients’ lives through science. Find out about our latest opportunity to help patients with serious cardiovascular disease https://bit.ly/36x7Wmn.

 

CEO Giovanni Caforio on Acquisition of MyoKardia

October 05, 2020 - 5 minute(s) read

Dear Colleagues,

Today we made an important announcement that we are acquiring MyoKardia, a San Francisco-based, clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative targeted cardiovascular (CV) therapeutics.

This significant planned transaction enhances the strength of Bristol Myers Squibb and will help position us for growth over the next decade. As we bring our companies together, we are excited to welcome a talented team with a shared commitment to transforming patients’ lives through science. We remain committed to our West Coast innovation hubs as centers of innovative drug discovery, which will be bolstered by MyoKardia’s diverse approach, skills and people and complement our wellestablished

CV drug discovery center in New Jersey.

We have been following MyoKardia’s innovative science over the years and have long admired what the MyoKardia teams have done to revolutionize cardiovascular treatments through a precision medicine approach. Like BMS, MyoKardia has focused its work on addressing significant unmet medical needs in patients with serious diseases.

With MyoKardia, we gain an outstanding lead asset – mavacamten – and a promising portfolio of pipeline candidates. Mavacamten is intended for the potential treatment of obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease with high morbidity and patient impact. HCM often goes undiagnosed and can be a debilitating condition, impairing the function of the heart and lowering patients’ quality of life. Mavacamten has demonstrated clinically meaningful Phase 3 results and we expect an NDA to be submitted to the FDA in the first quarter of 2021. We are encouraged by mavacamten’s significant potential to make a difference in the lives of patients with obstructive HCM, along with additional opportunities in other indications, including non-obstructive HCM.

I am incredibly proud of our CV franchise and the strong leadership position we have established with Eliquis. As you know, we have strong discovery and development teams and important work is underway to advance our FXIa inhibitor program and, with MyoKardia, we are accelerating the expansion of the franchise. Adding MyoKardia’s programs and outstanding translational research capabilities with our proven R&D expertise and commercial capabilities, we are strengthening our long-term prospects in this important therapeutic area.

Until the transaction closes, which we expect to occur in the fourth quarter of 2020, we will operate as independent companies. To address some of your initial questions, there is an FAQ available on BMS 360 and we expect to provide more information about MyoKardia and HCM in the coming weeks. I look forward to talking with you directly about this exciting opportunity at a company Q&A session on Wednesday, October 7, 2020, at 12 p.m. EDT.

Throughout this unprecedented year, we have consistently delivered superior results for our patients. We are delivering strong commercial performance, achieving significant pipeline milestones and maintaining an uninterrupted supply of our medicines. It is because of your efforts that we are able to invest in external innovation that complements our strong internal capabilities and advances our pipeline and portfolio.

This is an important next step in the company’s long-term strategy and I hope you are as excited as I am for the opportunity we are creating. I would like to thank the cross-functional team that worked tirelessly on this planned acquisition and congratulate them on today’s outcome. I would also like to thank all of you for your continued dedication to our mission and for all you do to help transform patients’ lives through science.

Best,

The information contained in this message is classified as BMS Internal and is intended for internal distribution only within Bristol Myers Squibb. You are expressly prohibited from forwarding all or part of this message or otherwise sharing its contents with anyone outside the company.

Additional Information and Where to Find It

The tender offer described in this report has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file with the U.S. Securities and Exchange Commission (“SEC”) a tender offer statement on Schedule TO. Investors and MyoKardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by MyoKardia with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.comor by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www.myokardia.com or by contacting MyoKardia at ir@myokardia.com, telephone number 650-351-4690.

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial documentretrieval services and at the website maintained by the SEC at www.sec.gov.

Forward Looking Statements

This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Bristol Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

---

Exhibit 99.7

BMS Employee FAQ

---

---